---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-345732"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2026-08-12T11:15:20+00:00"
generated_at: "2026-08-12T11:20:14.573401+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TScan Q2 net loss narrows to $30.4M; first patient dosed in Phase 3 ALLOHA-2 trial

## Summary
- Q2 2026 net loss $30.4M vs $37.0M; revenue $1.1M vs $3.1M, down on Amgen collaboration timing.
- Cash $100.2M at 6/30/26 funds ops into Q2 2027; missed debt milestones trigger term loan amortization from Q4 2026.
- First patient dosed in Phase 3 ALLOHA-2 (TSC-101, heme malignancies); topline expected mid-2028.
- Cohort C ALLOHA data: 79% (11/14) complete donor chimerism ~3 weeks post-TSC-101; ~90% (17/19) first-pass manufacturing success.
- TSC-102-A01 and TSC-102-A03 Phase 1 trials expected Q4 2026; solid-tumor IND roadmap by H2 2027 after FDA INTERACT engagement.

## SEC filing metadata
- accession: 0001193125-26-345732
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2026-08-12T11:15:20+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312526345732/0001193125-26-345732-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312526345732/tcrx-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-345732
- JSON: https://secwatch.observer/filing/0001193125-26-345732.json
- Plain text: https://secwatch.observer/filing/0001193125-26-345732.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.